Non-pegylated liposomal doxorubicin triple combination therapy
AssigneeSopherion Therapeutics, Inc.
InventorsMarcel Rozencweig, Ronald H. Goldfarb, Salvatore Forenza
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for treating metastatic breast cancer in an individual comprising administering to an individual in need thereof a dosing regimen which comprises administering to the individual nonpegylated liposomal doxorubicin, a taxane and a HER2/neu receptor antagonist, wherein the individual previously has been administered an anthracycline.
Claims13
A method for treating metastatic breast cancer in an individual previously treated with an anthracycline comprising administering to an individual in need thereof a dosing regimen which comprises at least one 3-week long treatment cycle, and wherein said individual is administered nonpegylated liposomal doxorubicin at a dose level of from 30 mg/m2 to 75 mg/m2 on day 1 of each treatment cycle, paclitaxel at a dose level of from 50 mg/m2 to 250 mg/m2 on day 1 of each treatment cycle, and trastuzumab at a dose level of from 3 mg/kg to 5 mg/kg as a loading dose on day 1 of the first treatment cycle and every week thereafter at a dose level of from 1 mg/kg to 3 mg/kg, and wherein said individual previously has been administered an anthracycline.
Dependencies are inferred from the claim text.